Dr. Reddy's Laboratories Ltd. - Form 6-K Filing

Dr. Reddy's Laboratories Limited has filed a Form 6-K report detailing an issue with certain batches of semaglutide. These batches were found to be out of specification due to a problem with the active pharmaceutical ingredient (API). The company is investigating the root cause and implementing corrective measures. Commercial supplies of the product will be temporarily delayed. Dr. Reddy's assures that there is no impact on patient safety or existing global regulatory filings. The company is committed to ensuring reliable global supplies of this metabolic therapy. A conference call is scheduled for July 9, 2026, to discuss the matter further. The company will provide an audio link and transcript of the call on its website.